Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.

  • Revenue in USD (TTM)50.28bn
  • Net income in USD5.85bn
  • Incorporated1994
  • Employees87.99k
  • Location
    Sanofi SA46 Avenue de la Grande ArmeePARIS 75017FranceFRA
  • Phone+33 153774000
  • Fax+33 153774463
  • Websitehttps://www.sanofi.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
SAN:PAR since
announced
Transaction
value
Mirati Therapeutics IncPrior rumour discounted06 Oct 202306 Oct 2023Prior rumour discounted-11.57%--
Quten Research Institute LLC-QunolDeal completed28 Jul 202328 Jul 2023Deal completed-6.95%--
Data delayed at least 15 minutes, as of Mar 28 2024 16:35 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Zoetis Inc8.54bn2.34bn77.16bn14.10k33.2315.4627.259.035.075.0718.4810.900.5851.036.78605,957.4016.0214.4719.3717.1870.4769.8027.3925.772.0017.150.568226.895.747.9610.8811.1316.7124.37
Gilead Sciences, Inc.27.12bn5.66bn90.95bn18.00k16.213.9810.953.354.504.5021.5618.330.43283.955.751,506,445.008.966.7410.918.1276.0478.6420.6916.951.277.630.523481.22-0.60484.1523.370.7436-8.745.64
Regeneron Pharmaceuticals Inc13.12bn3.95bn106.06bn13.45k27.804.0724.258.0934.7634.76115.32237.410.42110.72892.39975,256.5012.6920.1814.1923.2286.1686.6330.1438.114.94--0.0943--7.7614.34-8.8710.7219.32--
Bristol-Myers Squibb Co45.01bn8.03bn107.68bn34.10k13.803.666.052.393.863.8621.6614.560.46894.245.011,319,824.008.383.0510.893.7676.4476.1317.867.691.3112.390.5743133.63-2.5014.8126.8410.034.927.34
Vertex Pharmaceuticals Incorporated9.87bn3.62bn107.80bn5.40k30.046.1228.3610.9213.8913.8937.8868.220.48282.106.571,827,630.0017.7119.9220.9323.6487.2187.6736.6835.853.78--0.0210.0010.5126.498.9646.5022.02--
Sanofi SA (ADR)50.28bn5.85bn125.70bn87.99k21.281.5515.032.502.332.3320.0532.030.36691.535.51571,407.104.385.875.437.1669.3568.7811.9516.900.867566.190.1986--2.325.42-35.494.578.87--
Amgen Inc28.19bn6.72bn153.43bn26.70k22.9224.6014.225.4412.4912.4952.4211.640.34741.164.391,055,805.008.2810.3610.4813.0670.1675.4123.8326.511.133.150.91259.547.093.492.52-4.368.5410.04
Pfizer Inc58.50bn2.13bn157.31bn88.00k77.331.7618.592.690.35930.356610.2915.770.27611.885.29664,738.601.038.201.3010.4069.2469.343.7122.680.6935--0.44660.11-41.707.46-93.20-7.9412.213.82
Data as of Mar 28 2024. Currency figures normalised to Sanofi SA's reporting currency: US Dollar USD

Institutional shareholders

5.87%Per cent of shares held by top holders
HolderShares% Held
Dodge & Coxas of 31 Dec 202378.25m3.09%
Fisher Asset Management LLCas of 31 Dec 202314.29m0.57%
Boston Partners Global Investors, Inc.as of 31 Dec 202313.03m0.52%
Fidelity Management & Research Co. LLCas of 31 Dec 20238.89m0.35%
Strategic Advisers LLCas of 31 Dec 20237.98m0.32%
Managed Account Advisors LLCas of 31 Dec 20237.10m0.28%
Invesco Advisers, Inc.as of 31 Dec 20236.07m0.24%
BlackRock Investment Management LLCas of 31 Dec 20235.48m0.22%
Newton Investment Management North America LLCas of 31 Dec 20233.87m0.15%
FIAM LLCas of 31 Dec 20233.51m0.14%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.